Skip to main content

Table 2 Clinical, echocardiographic and hemodynamic characteristics of DCM and ICM patients

From: Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study

 

CONT

DCM

ICM

Number of samples

5

5

5

Gender (female/male)

3/2

2/3

4/1

Age (year)

29 ± 9

39 ± 10

57 ± 11*#

NYHA functional class III/IV, n

n.a.

0/5

3/2

PAP, mmHg

n.a.

31.6 ± 4.7

30.8 ± 5.6

PWP, mmHg

n.a.

24 ± 4.3

21 ± 3.5

LVED, mm

n.a.

68 ± 4

71 ± 4

LVSD, mm

n.a.

63 ± 5

61 ± 8

PW, mm

n.a.

9.5 ± 0.5

10 ± 1.5

IVS, mm

n.a.

10 ± 0.7

11 ± 1.5

LVEF, %

n.a.

16 ± 3

23 ± 3

Medications

   

ACE-inhibitor

-

++

++

β-Blocker

-

++

++

Diuretics

-

++

++

Digitalis

-

+

+

PDE-inhibitor

-

++

++

Dopamine/Noradrenaline

++

++

+

Statin

-

-

++

Aspirin

-

-

++

Desmopressin

++

-

-

  1. Values are given in mean ± SEM; *p < 0.05 compared to control; #p < 0.05 compared to DCM Abbreviations: CONT: healthy control individuals, DCM: dilated cardiomyopathy, ICM: ischemic cardiomyopathy, NYHA: New York Heart Association, PAP: mean pulmonary artery pressure, PWP: mean pulmonary wedge pressure, LVED: left ventricular end-diastolic diameter, LVSD: left ventricular end-systolic diameter, PW: posterior wall thickness, IVS: interventricular septum thickness, LVEF: left ventricular ejection fraction, ACE: angiotensin converting enzyme, PDE: phosphodiesterase, n.a.: not applicable.